Novo Nordisk has announced plans to move its ziltivekimab into phase 3 clinical development in atherosclerosis with chronic kidney disease after a mid-stage trial met its main goal.

In this regard Novo Nordisk is leading the way. We've become increasingly committed to chronic conditions that include cardiovascular disease and chronic kidney disease – the reason being ...

With VKTX surging on clinical results and NVO investing to cement market share, investors face a high-stake GLP-1 showdown.

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Data across obesity, cardiovascular disease, MASH, type 2 diabetes ... Denmark, 6 May 2025 – Novo Nordisk today announced that new data spanning the company’s industry-leading portfolio ...

LONDON, GREATER LONDON, UNITED KINGDOM, May 23, 2025 /EINPresswire.com/ -- The Business Research Company’s Latest Report Explores Market Driver, Trends, Regional Insights - Market Sizing & Forecasts ...

Novo Nordisk’s type 2 diabetes drug Ozempic has expanded its label to include chronic kidney disease. The new FDA approval comes as makers of GLP-1 drugs work to expand the uses of these products.

Novo Nordisk’s Wegovy (semaglutide injection) 2.4mg has demonstrated early protection against heart disease, according to new data from a late-stage study of the GLP-1 receptor agonist.

The Odessa American is the leading source of local news, information, entertainment and sports for the Permian Basin.

Novo Nordisk A/S NVO shares lost 2.7% on ... Ozempic is also indicated for treating chronic kidney disease and Wegovy received FDA approval last year to reduce the risk of heart disease.